Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 3;4(5):e1003012.
doi: 10.1080/2162402X.2014.1003012. eCollection 2015 May.

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

Nathalie Vigneron  1 , Nicolas van Baren  2 , Benoît J Van den Eynde  1
Affiliations

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

Nathalie Vigneron et al. Oncoimmunology. .

Abstract

Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO1 was also expressed in 56% of tumors, either by tumoral, stromal, or endothelial cells. These results and reagent will guide the clinical development of IDO1 inhibitors for cancer therapy.

Keywords: dendritic cells; immunohistochemistry; immunosuppression; indoleamine 2,3-dioxygenase; tryptophan; tumor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
IDO1 Protein expression in human tumors assessed by immunohistochemistry. Illustrative images from formalin-fixed paraffin-embedded tissue microarray sections of cervical (A, B) and endometrial carcinomas (C, D) stained with the anti-IDO1 antibody 4.16H1. Tumoral (T), stromal (S), and lymphocyte-enriched (L) areas are indicated. Immunolabeled cells are stained dark red.
See this image and copyright information in PMC

References

    1. Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, et al.. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 2015; 3(2):161–72; PMID: ; http://dx.doi.org/10.1158/2326-6066.CIR-14-0137 - DOI - PubMed
    1. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, et al.. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722–35; PMID:; http://dx.doi.org/10.1158/2159-8290.CD-12-0014 - DOI - PMC - PubMed
    1. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, et al.. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16:279–85; PMID:; http://dx.doi.org/10.1038/nm.2092 - DOI - PMC - PubMed
    1. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83:1457–66; PMID:; http://dx.doi.org/10.1097/01.LAB.0000090158.68852.D1 - DOI - PubMed
    1. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3; PMID:; http://dx.doi.org/10.1186/2051-1426-2-3. - DOI - PMC - PubMed

LinkOut - more resources